+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non-Cystic Fibrosis Bronchiectasis (NCFB) - Pipeline Insight, 2020

  • ID: 4989213
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 106 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Alaxia SAS
  • Zambon SpA
  • MORE
Non-Cystic Fibrosis Bronchiectasis (NCFB) Overview

Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Non-Cystic Fibrosis Bronchiectasis (NCFB) market. A detailed picture of the Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline landscape is provided, which includes the disease overview and Non-Cystic Fibrosis Bronchiectasis (NCFB) treatment guidelines. The assessment part of the report embraces in-depth Non-Cystic Fibrosis Bronchiectasis (NCFB) commercial assessment and clinical assessment of the Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Cystic Fibrosis Bronchiectasis (NCFB) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Non-Cystic Fibrosis Bronchiectasis (NCFB) of pipeline development activities

The report provides insights into:
  • All of the companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB) with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Non-Cystic Fibrosis Bronchiectasis (NCFB) treatment.
  • Non-Cystic Fibrosis Bronchiectasis (NCFB) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Non-Cystic Fibrosis Bronchiectasis (NCFB) market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Analytical Perspective

In-depth Non-Cystic Fibrosis Bronchiectasis (NCFB) Commercial Assessment Of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Clinical Assessment Of Products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Non-Cystic Fibrosis Bronchiectasis (NCFB) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Non-Cystic Fibrosis Bronchiectasis (NCFB) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Non-Cystic Fibrosis Bronchiectasis (NCFB) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Non-Cystic Fibrosis Bronchiectasis (NCFB) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Non-Cystic Fibrosis Bronchiectasis (NCFB) .
Report Highlights
  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Non-Cystic Fibrosis Bronchiectasis (NCFB) .
  • In the coming years, the Non-Cystic Fibrosis Bronchiectasis (NCFB) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Non-Cystic Fibrosis Bronchiectasis (NCFB) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Non-Cystic Fibrosis Bronchiectasis (NCFB) treatment market. Several potential therapies for Non-Cystic Fibrosis Bronchiectasis (NCFB) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Non-Cystic Fibrosis Bronchiectasis (NCFB) market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB) ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions
  • What are the current options for Non-Cystic Fibrosis Bronchiectasis (NCFB) treatment?
  • How many companies are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB)?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB)?
  • How many Non-Cystic Fibrosis Bronchiectasis (NCFB) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB)?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Non-Cystic Fibrosis Bronchiectasis (NCFB) market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB)?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Non-Cystic Fibrosis Bronchiectasis (NCFB) therapies?
  • What are the clinical studies going on for Non-Cystic Fibrosis Bronchiectasis (NCFB) and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Non-Cystic Fibrosis Bronchiectasis (NCFB)?
  • How many patents are granted and pending for the emerging therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB)?


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alaxia SAS
  • Zambon SpA
  • MORE
1. Report Introduction

2. Non-Cystic Fibrosis Bronchiectasis (NCFB)
2.1. Overview
2.2. History
2.3. Non-Cystic Fibrosis Bronchiectasis (NCFB) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosis
2.6.1. Diagnostic Guidelines

3. Non-Cystic Fibrosis Bronchiectasis (NCFB) Current Treatment Patterns
3.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Guidelines

4. Non-Cystic Fibrosis Bronchiectasis (NCFB) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Non-Cystic Fibrosis Bronchiectasis (NCFB) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Non-Cystic Fibrosis Bronchiectasis (NCFB) Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Non-Cystic Fibrosis Bronchiectasis (NCFB) Late Stage Products (Phase-III)

7. Non-Cystic Fibrosis Bronchiectasis (NCFB) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Cystic Fibrosis Bronchiectasis (NCFB) Discontinued Products

13. Non-Cystic Fibrosis Bronchiectasis (NCFB) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Non-Cystic Fibrosis Bronchiectasis (NCFB) Key Companies

15. Non-Cystic Fibrosis Bronchiectasis (NCFB) Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Non-Cystic Fibrosis Bronchiectasis (NCFB) Unmet Needs

18. Non-Cystic Fibrosis Bronchiectasis (NCFB) Future Perspectives

19. Non-Cystic Fibrosis Bronchiectasis (NCFB) Analyst Review

20. Appendix

21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Zambon SpA
  • Chiesi Farmaceutici S.p.A.
  • Alaxia SAS
Note: Product cover images may vary from those shown
Adroll
adroll